Tradestie Institutional Equity Comparison Engine
MUSE vs INKT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
INKT Overall Edge
INKT Captures Institutional Edge (1โ1 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MiNK Therapeutics, Inc. Common Stock (INKT) driven by superior Growth & Margin while MUSE counters with relative strength in Momentum & Technical. Fundamentally, MUSE trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus INKT at N/M Forward P/E and -5720.7% operating margin (+0.0% YoY). In options structure, MUSE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against INKT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
MUSE N/M vs INKT N/M Fwd P/E
Growth & Margin Winner
INKT
Op Margin N/A vs -5720.7% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
MUSE
1Y -6.0% vs -27.2% ยท 52W Pos 0% vs 3%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
MUSE
US Equity
MUSE
Institutional Equity
$47.67
-0.13% 1D
Market Cap
N/A
1M Return
-0.65%
1Y Return
-6.03%
Forward P/E
N/M
Unified AI Score
45.9 / 100
HOLD
Tech 48.0
Fund 50.0
Flow 50.0
Mom 60.0
INKT
NASDAQ
MiNK Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$8.02
-6.85% 1D
Market Cap
$44.2M
1M Return
-20.28%
1Y Return
-27.22%
Forward P/E
N/M
Unified AI Score
42.8 / 100
HOLD
Tech 33.0
Fund 45.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MUSE -6.03%
INKT -27.22%
Spread: +21.9 pp (MUSE Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MUSE TTM Op. Margin: N/A
INKT TTM Op. Margin: -5720.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MUSE vs INKT. Trailing 12-month operating profitability (MUSE N/A vs INKT -5720.7%) and valuation multiples (MUSE N/M vs INKT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MUSE | INKT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $44.2M | Larger Scale | INKT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | INKT |
| Operating Margin (TTM) Profitability | N/A | -5720.7% | Higher Margin | INKT |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | INKT |
| Return on Equity (ROE) Capital Efficiency | N/A | -1239.0% | Higher ROE | INKT |
| 52-Week Range Position Momentum | 0% ($48โ$52) | 3% ($8โ$17) | Stronger Trend | INKT |
| Beta / 30D Volatility Risk Regime | 0.10ฮฒ ยท 4% Vol | 0.59ฮฒ ยท 55% Vol | Lower Realized Risk | MUSE |
| Unified Institutional Score Composite Signal | 45.9 / 100 (HOLD) | 42.8 / 100 (HOLD) | Higher Composite | MUSE |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MUSE vs INKT Buy Guide
MUSE
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
INKT
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MUSE nor INKT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.